Papers/PMID:35334570
Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial.
Medicina (Kaunas, Lithuania)2022The record
1 finding drawn from this paper, on 1 compound across 1 endpoint, 1 of them null.
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
L-glutamine — no detected effect on all-cause mortality
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull resultreplicated ×2“The mortality rate was insignificantly different between glutamine group and placebo group (22.7% vs. 36.4% respectively, p-value = 0.509) as presented in Table 4 and.”
Quoted verbatim from Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial.. - Study
- RCT
- Participants
- 44
- Dose
- 20 gm/100 mL intravenous N(2)-L-Alanyl-L-Glutamine Dipeptide (Dipeptiven) on the day 1-2 regimen every 2 weeks
- Population
- Stage II and III colon cancer patients, both arms receiving identical mFOLFOX-6 chemotherapy, randomised to intravenous L-alanyl L-glutamine dipeptide or placebo; mortality over the trial follow-up